Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGN 101

Drug Profile

IGN 101

Alternative Names: Cancer vaccine (IGN101) - Aphton; Cancer vaccine - Igeneon

Latest Information Update: 17 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Developer Altropus
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 05 Nov 2009 Clinical development is ongoing in Europe
  • 03 Jun 2008 Efficacy data from a Phase II/III trial in Non-small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 07 Feb 2006 Pending directorship approval, Igeneon intends give Celltrion the right of first refusal to further develop and commercialise IGN 101
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top